Hospital

Ibrutinib combined with venetoclax significantly improved measurable residual disease and progression-free survival in patients with chronic lymphocytic leukemia.

The FDA approves donidalorsen, the first RNA-targeted therapy for hereditary angioedema, offering significant attack reduction and convenient administration.

New research uncovers complex inflammatory pathways driving asthma flare-ups in children, highlighting the need for personalized treatment strategies.

New research uncovers a pathway linking diabetes and heightened blood clot risks, paving the way for innovative treatments to prevent cardiovascular complications.

Research reveals that clinical stage significantly influences survival rates in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.

Signos CGM empowers users to manage weight effectively through personalized insights and real-time glucose tracking.

Both preclinical and translational evidence support MET inhibition as a therapeutic approach in patients with small cell lung cancer (SCLC).

New research reveals that immunoglobulin replacement therapy fails to lower infection-related hospitalizations in those with chronic lymphocytic leukemia (CLL), raising treatment concerns.

Unicycive Therapeutics secures a US patent for UNI-494, a promising treatment for chronic kidney disease, enhancing its development and partnership potential.

Virtual health care enhances patient experiences, integrates complex data, and ensures medication access through provider-pharmacist collaboration.

Combination therapy with tremelimumab and durvalumab significantly improves survival in patients with liver cancer compared with standard sorafenib treatment.

Morgan Cantley, PharmD, BCOP, shares key insights about the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan.

Many adults remain unaware of HPV's cancer risks, highlighting the urgent need for increased awareness.

IDSA updated cUTI guidelines for men and women emphasize antibiotic selection, transition to oral therapy, and optimal treatment duration.

Revumenib shows promise in treating NPM1-mutant AML, expanding its role in precision oncology and offering hope for targeted leukemia therapies.

CT-155, an investigational prescription digital therapeutic, was found to improve motivation, sociality, and other negative symptoms in patients with schizophrenia as an adjunct to antipsychotic treatment.

New findings highlight environmental impacts on weight management.

Aficamten offers new hope for HCM patients, showing significant clinical benefits and safety in recent trials, enhancing treatment options.

Acalabrutinib shows improved safety and survival rates in chronic lymphocytic leukemia (CLL), reducing risks of mortality and cardiovascular complications.

The designation is supported by promising results from the ongoing phase 1/2 BEACON clinical trial.

A collaborative care model enhances education and management for patients with chronic kidney disease, improving outcomes and understanding.

Stiff Person Syndrome has unique complexities, necessitating the role of pharmacists in managing its symptoms and treatment options.

Elicio Therapeutics' ELI-002 2P cancer vaccine shows promising survival benefits in patients with pancreatic and colorectal cancer, enhancing immune responses.

RSV vaccination rates among older adults remain low despite new vaccines, highlighting disparities in uptake and the need for targeted outreach.

TAR-200 shows promise in treating BCG-unresponsive bladder cancer, achieving 82% tumor elimination and offering new hope for patients.

Health care automation enhances efficiency, yet medication inventory visibility remains a challenge.